MODERN PARADIGM OF THE PREGNANT-INVOLVING PHARMACOLOGICAL STUDY: RISK ASSESSMENT, ETHICAL PRINCIPLES AND REGULATORY ASPECT
https://doi.org/10.15690/pf.v11i2.953
Abstract
This article is dedicated to the issue of studying drug efficacy and safety in pregnant women, i.e. to their participation in clinical studies. The authors emphasize that lack of evidence base on drug use makes physicians helpless against diseases and gestational pathological conditions. The authors demonstrate results of the completed clinical studies involving pregnant women. In this article, they analyze possible risks and ethical complications of pregnant women taking part in clinical studies, as well as modern possibilities of medicine and legislative base of a range of countries, which allow minimizing risks of taking part in a study both for mothers and their fetuses. The authors demonstrate that the international experience of resolving ethical and legal issues of clinical studies among children may facilitate settlement of many problems of this issue.
About the Authors
K. A. Lutsevich
Razumovskiy Saratov State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, assistant professor at the pharmacology department of Razumovskii Saratov State Medical University of the Ministry of Health of the RF (State Budgetary Educational Institution of Higher Professional Education)
O. V. Reshetko
Razumovskiy Saratov State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
T. S. Lutsevich
Razumovskiy Saratov State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Lyerly A.D., Little M.O., Faden R. The second wave: Toward responsible inclusion of pregnant women in research. Int. J. Fem. Approaches Bioeth. 2008; 1(2): 5–22.
2. Zavidova S.S., Topolyanskaya S.V., Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pedatric pharmacology. 2010; 7(1):6-14.
3. Dunlop A.L., Gardiner P.M., Shellhaas C.S. et al. The clinical content of preconception care: the use of medications and supplements among women of reproductive age. Am J Obstet Gynecol. 2008; Supplement to December: 367–372.
4. Koren G. Pharmacokinetics in pregnancy; clinical significance. J. Popul. Ther. Clin. Pharmacol. 2011; 18: 523–527.
5. Parisi M. A., Spong C. Y., Zajicek A., Guttmacher A. E. We don't know what we don't study: the case for research on medication effects in pregnancy. Am. J. Med. Genet. C Semin Med. Genet. 2011; 157: 247–250.
6. Giacoia G., Mattison D. Obstetric and Fetal Pharmacology. Glob libr women's med (ISSN: 1756–2228). 2009.
7. McCullough L. B., Coverdale J. H., Chervenak F. A. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am. J. Obstet Gynecol. 2005; 193: 901–907.
8. Longo L. D., Jaffe R. B. A challenge for the 21st century: whither physician-scientists in obstetrics, gynecology, and the reproductive sciences? Am. J. Obstet Gynecol. 2008; 198: 489–495.
9. Horgan R. P., Clancy O. H., Myers J. E., Baker P. N. An overview of proteomic and metabolomic technologies and their application to pregnancy research. BJOG. 2009; 116: 173–181.
10. Wilffert B., Altena J., Tijink L. et al. Pharmacogenetics of druginduced birth defects: what is known so far? Pharmacogenomics. 2011; 12: 547–558.
11. Dominguez V., Ramos N., Torrents A. et al. Clinical trials during pregnancy: what has been done. Eur. J. Clin. Pharmacol. 2012; 68: 455–458.
12. Koren G. Is it appropriate to study the pharmacokinetics of drugs aimed at pregnant women in men? J. Obstet Gynaecol. Can. 2010; 32: 629–630.
13. Uhl K., Parekh A., Kweder S. Females in clinical studies: where are we going? Clin. Pharmacol. Ther. 2007; 81: 600–602.
14. Anderson G. D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J. Women’s Health. 2005; 14: 19–29.
15. Chen M. L., Lee S. C., Ng M. J. et al. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin. Pharmacol. Ther. 2000; 68: 510–521.
16. Bourget P., Roulot C., Fernandez H. Models for placental transfer studies of drugs. Clin. Pharmacokinet. 1995; 28: 161–180.
17. Gedeon C., Nava-Ocampo A. A., Koren G. Ethical issues in pharmacologic research in women undergoing pregnancy termination: a systemic review and survey of researchers. Obstet Gynecol. Int. 2012; 2012: 724591.
18. Anderson F., Glasier A., Ross J., Baird D. T. Attitudes of women to fetal tissue research. J. Med. Ethics. 1994; 20: 36–40.
19. Goldkind S. F., Sahin L., Gallauresi B. Enrolling pregnant women in research — lessons from the H1N1 influenza pandemic. N. Engl. J. Med. 2010; 362: 2241–2243.
20. Hines R. N., Sargent D., Autrup H. et al. Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population. Toxicol. Sci. 2010; 113: 4–26.
21. Ivanova A.A., Mikhailov A.V., Kolbin A.S. Pediatricheskaya farmakologiya = Pedatric pharmacology. 2013; 10(1): 46–53.
22. Sher S.A. Pediatricheskaya farmakologiya = Pedatric pharmacology. 2011; 8(6): 57–60.
23. Jelinek R. The contribution of new findings and ideas to the old principles of teratology. Reprod Toxicol. 2005; 20: 295–300.
24. Widmer N., Meylan P., Ivanyuk A. et al. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin. Pharmacokinet. 2010; 49: 741–765.
25. Beigi R. H., Han K., Venkataramanan R. et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am. J. Obstet Gynecol. 2011; 204 (6 Suppl.): 84–88.
26. Greer L. G., Leff R. D., Rogers V. L. et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am. J. Obstet Gynecol. 2011; 204 (6 Suppl.): 89–93.
27. Andrew M. A., Easterling T. R., Carr D. B. et al. Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of dosage strategies. Clin. Pharmacol. Ther. 2007; 81: 547–556.
28. Hebert M. F., Ma X., Naraharisetti S. B. et al. Are we optimizing gestational diabetes treatment with glyburide the pharmacologic basis for better clinical practice? Clin. Pharmacol. Ther. 2009; 85: 607–614.
29. Langer O., Conway D. L., Berkus M. D. et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med. 2000; 343: 1134–1138.
30. Rowan J. A., Hague W. M., Gao W. et al. Metformin versus insulin for the treatment of gestational diabetes. N. Engl. J. Med. 2008; 358: 2003–2015.
31. Eyal S., Easterling T. R., Carr D. et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010; 38: 833–840.
32. Roberts J. M., Hubel C. A. The two stage model of preeclampsia: variations on the theme. Placenta. 2009; 30 (Suppl.): 32–37.
33. Hogstedt S., Lindberg B., Peng D. R. Pregnancy-induced increase in metoprolol metabolism. Clin. Pharmacol. Ther. 1985; 37: 688–692.
34. Hogstedt S., Rane A. Plasma concentration-effect relationship of metoprolol during and after pregnancy. Eur. J. Clin. Pharmacol. 1993; 44: 243–246.
35. Hebert M. F., Carr D. B., Anderson G. D. et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J. Clin. Pharmacol. 2005; 45: 25–33.
36. McDonald K., Amir L. H., Davey M. A. Maternal bodies and medicines: a commentary on risk and decision-making of pregnant and breastfeeding women and health professionals. BMC Public Health. 2011; 11 (Suppl. 5): 5.
37. Reshet'ko O.V., Lutsevich K.A. Voprosy ginekologii, akusherstva i perinatalogii - Problems of gynecology, obstetrics and perinatology. 2013; 12(2): 52–60.
38. Artama M., Gissler M., Malm H., Ritvanen A. Nationwide registerbased surveillance system on drugs and pregnancy in Finland 1996–2006. Pharmacoepidemiol Drug. Saf. 2011; 20: 729–738.
39. Erdeljic V., FranceticI., Makar-Ausperger K. et al. Clinical pharmacology consultation: a better answer to safety issues of drug therapy during pregnancy? Eur. J. Clin. Pharmacol. 2010; 66: 1037–1046.
40. Uhl K., Trontell A., Kennedy D. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools. Pharmacoepidemiol Drug. Saf. 2007; 16: 337–348.
41. Macklin R. Enrolling pregnant women in biomedical research. Lancet. 2010; 375: 631–633.
42. Haas D. M., Gallauresi B., Shields K. et al. Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy. Clin. Transl. Sci. 2011; 4: 204–209.
43. Randy L. Jirtle. PhD: epigenetics a window on gene dysregulation, disease. Interview by Bridget M. Kuehn. JAMA. 2008; 299: 1249–1250.
44. Chauvenet M., Rimailho A., Hoog-Labouret N. Methodology for the evaluation of drugs in pregnant women. Therapie. 2003; 58: 247–258.
45. Anger G. J., Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin. Pharmacol. Ther. 2008; 83: 184–187.
46. Coverdale J. H., McCullough L. B., Chervenak F. A. The ethics of randomized placebo-controlled trials of antidepressants with pregnant women: a systematic review. Obstet Gynecol. 2008; 112: 1361–1368.
47. Baylis F., Kaposy C. Wanted: Inclusive guidelines for research involving pregnant women. J. Obstet Gynaecol. Can. 2010; 32: 473–476.
48. Chambers C. D., Polifka J. E., Friedman J. M. Drug safety in pregnant women and their babies: ignorance not bliss. Clin. Pharmacol. Ther. 2008; 83: 181–183.
49. Little M. O., Lyerly A. D., Faden R. R. Pregnant women & medical research: a moral imperative. Bioethica Forum. 2009; 2: 60–65.
50. Rodger M. A., Makropoulos D., Walker M. et al. Participation of pregnant women in clinical trials: Will they participate and why? Am. J. Perinatol. 2003; 20: 69–76.
51. Reshet'ko O.V., Lutsevich K.A. Remedium = Remedium. 2012; 7: 57–61.
52. Rayburn W., Anderson J., Smith C. V. et al. Uterine and fetal Doppler flow changes from a single dose of long-acting intranasal decongestant. Obstet Gynecol. 1990; 76: 180–182.
53. Herring C., McManus A., Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women’s Hospital. Int. J. Pharm. Pract. 2010; 18: 226–229.
54. Baird K. L. The new NIH and FDA medical research policies: targeting gender, promoting justice. J. Health Polit. Policy Law. 1999; 24: 531–565.
Review
For citations:
Lutsevich K.A., Reshetko O.V., Lutsevich T.S. MODERN PARADIGM OF THE PREGNANT-INVOLVING PHARMACOLOGICAL STUDY: RISK ASSESSMENT, ETHICAL PRINCIPLES AND REGULATORY ASPECT. Pediatric pharmacology. 2014;11(2):22-29. https://doi.org/10.15690/pf.v11i2.953
Views:
1107
Email this article 